Mori, S.; Ai, T.; Sera, T.; Ochiai, K.; Otomo, Y.
Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes. J. Clin. Med. 2019, 8, 1553.
https://doi.org/10.3390/jcm8101553
AMA Style
Mori S, Ai T, Sera T, Ochiai K, Otomo Y.
Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes. Journal of Clinical Medicine. 2019; 8(10):1553.
https://doi.org/10.3390/jcm8101553
Chicago/Turabian Style
Mori, Shusuke, Tomohiko Ai, Toshiki Sera, Kanae Ochiai, and Yasuhiro Otomo.
2019. "Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes" Journal of Clinical Medicine 8, no. 10: 1553.
https://doi.org/10.3390/jcm8101553
APA Style
Mori, S., Ai, T., Sera, T., Ochiai, K., & Otomo, Y.
(2019). Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes. Journal of Clinical Medicine, 8(10), 1553.
https://doi.org/10.3390/jcm8101553